Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05053152
Other study ID # NRG-GU011
Secondary ID NCI-2021-09164NR
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 8, 2021
Est. completion date October 10, 2029

Study information

Verified date February 2024
Source NRG Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.


Description:

PRIMARY OBJECTIVE: I. Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET)-detected, biochemically recurrent, oligometastatic, castration-sensitive prostate cancer patients treated with stereotactic ablative body radiation therapy (SABR) plus placebo versus (vs.) SABR plus relugolix. SECONDARY OBJECTIVES: I. Compare conventional or PET-based radiological progression-free survival (prPFS) between treatment arms. II. Compare patient-reported sexual and hormonal quality of life as assessed by corresponding Expanded Prostate Cancer Index Composite Short Form (EPIC-26) domains between treatment arms. III. Compare other measures of quality of life obtained from the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ5D-5L), European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-30), and Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue instruments between the two treatment arms. IV. Compare time to salvage therapy and time to castration-resistance between treatment arms. V. Compare local progression (SABR-targeted lesion), biochemical progression, distant metastases, prostate cancer-specific mortality, metastasis-free survival, and overall survival between treatment arms. VI. Determine adverse events rates and compare rates between the two treatment arms. EXPLORATORY OBJECTIVE: I. Evaluate genomic and peripheral tissue and blood markers of treatment response. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive placebo orally (PO) once daily (QD) on days 1-180 (three tablets on Day 1, one tablet daily on Days 2-180) and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive relugolix PO QD on days 1-180 (three tablets on Day 1, one tablet daily on Days 2-180) and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 3 and 6 months, every 6 months for 4 years, and then annually thereafter.


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date October 10, 2029
Est. primary completion date October 10, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration - Age = 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 120 days prior to registration - Prior curative-intent treatment to the prostate, by either: - External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites - Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes - Must meet study entry criteria based on the following diagnostic workup within 120 days prior to registration: - History and physical examination; - Technetium TC-99m (99mTc) bone scan (Must be negative); - Either computed tomography (CT) or magnetic resonance imaging (MRI) of pelvis +/- abdomen (Must be negative); - Fluciclovine or prostate-specific membrane antigen (PSMA) PET scan (Must be positive with exception of local disease); - Note: All 3 scans are mandatory (bone scan; CT/magnetic resonance [MR]; PET) - 1 - 5 oligometastatic lesions in bone and/or nodal/soft tissue sites on fluciclovine or PSMA PET within 120 days prior to registration and includes at least ONE of the following: - Bone - each metastasis is counted (for example, 2 distinct lesions in the right ilium count as 2 oligometastatic lesions) - Extrapelvic Nodal/ soft tissue - requires at least one extrapelvic inguinal or a nodal/soft tissue lesion superior to the iliac bifurcation (that is, American Joint Committee on Cancer [AJCC] M1a version 8) - Note: Although a patient must have bone and/or extrapelvic disease to be eligible, when counting the number of oligometastatic lesions, each lymph node lesion, whether pelvic or extrapelvic, is counted (for example, 2 distinct lymph nodes in the right external iliac basin count as 2 oligometastatic lesions; one extrapelvic and one pelvic node count as 2 oligometastic lesions, etc) - Serum total prostate-specific antigen (PSA) =10.0 ng/mL obtained within 120 days prior to registration that also meets ONE of the following PSA recurrence definitions: - PSA = post-radiation therapy (RT) nadir PSA + 2 ng/mL, if patient received-radiation therapy to intact prostate, or - Current PSA = 0.2 ng/mL, with a second confirmatory PSA = 0.2 ng/mL if patient received a radical prostatectomy with or without post-op RT - Must have =3 PSA values within the last two years since end of primary treatment or within the last 2 years prior to registration, whichever is less - Note: PSA doubling time must be calculated by entering all PSA values since end of primary treatment or within the last 2 years prior to registration (whichever is less) into the PSA Doubling Time Calculator found at MDCalc.com - Serum total testosterone = 100 ng/dL within 120 days prior to registration - Note: Prior androgen deprivation therapy (other than bilateral orchiectomy) is allowed if discontinued prior to registration and serum total testosterone is = 100 ng/dL - Total bilirubin: = 1.5 x institutional upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, subject is eligible if direct bilirubin is = 1.5 x ULN) (within 120 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]): = 2.5 x institutional ULN (within 120 days prior to registration) - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial - The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information. Exclusion Criteria: - Clinical, biopsy-proven, or radiologic (conventional or PET imaging) evidence of local tumor recurrence in the prostate and/or periprostatic/seminal vesicle region after radiotherapy, or in the prostate bed after prostatectomy - Note: if a patient had a prior local recurrence and received local salvage therapy, the patient is eligible if there is no current evidence of disease in the prostate/prostate bed. Patients with positive findings on examination or imaging remain eligible if biopsy of the site is negative for cancer. - Currently on androgen deprivation or anti-androgen therapy - Definitive radiologic evidence of metastatic disease on conventional imaging, defined by one of the following: - Osseous metastasis on 99mTc radionuclide bone scan, or - Extra pelvic nodal/soft tissue disease (> 1.5 cm in short axis) on CT or MRI pelvis +/- abdomen - Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver, lung, etc.) metastasis - Note: Spinal metastases (PET-detected) with epidural extension are eligible if there is > 0.3 cm spatial separation between the gross tumor volume and spinal cord. - Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell) - Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, non-melanomatous skin cancer) unless continuously disease free for = 3 years - Prior chemotherapy for prostate cancer or bilateral orchiectomy - Note: Prior chemotherapy for a different cancer is allowed if continuously disease-free for = 3 years - Prior radiotherapy to a lesion (i.e. oligometastatic recurrence by PET) - Note: Lesions outside of a previously irradiated planning treatment volume (PTV) are eligible as long as the prescription isovolume dose of any prior radiotherapy course is > 2.0 cm distant from new lesion - Inability to treat all oligometastatic sites with radiotherapy in the judgement of the investigator - Intrapelvic lymph nodes as only site of prostate cancer recurrence - Inability to swallow whole, undivided, unchewed, and uncrushed pills - Known gastrointestinal disorder affecting oral medication absorption - Co-morbidity defined as follows: - Patients with any comorbidities that would prohibit completion of protocol specified therapy - Inflammatory bowel disease in patients in whom abdominopelvic radiotherapy is planned - History of congenital long QT syndrome - Current severe or unstable angina - New York Heart Association functional classification III/IV heart failure (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo Administration
Given PO
Other:
Quality-of-Life Assessment
Ancillary studies
Drug:
Relugolix
Given PO
Radiation:
Stereotactic Body Radiation Therapy
Undergo SABR

Locations

Country Name City State
Canada University Health Network-Princess Margaret Hospital Toronto Ontario
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States UPMC Altoona Altoona Pennsylvania
United States Mary Greeley Medical Center Ames Iowa
United States McFarland Clinic - Ames Ames Iowa
United States Saint Joseph Mercy Hospital Ann Arbor Michigan
United States Langlade Hospital and Cancer Center Antigo Wisconsin
United States Emory Saint Joseph's Hospital Atlanta Georgia
United States Emory University Hospital Midtown Atlanta Georgia
United States Emory University Hospital/Winship Cancer Institute Atlanta Georgia
United States Grady Health System Atlanta Georgia
United States Piedmont Hospital Atlanta Georgia
United States UCHealth University of Colorado Hospital Aurora Colorado
United States UH Seidman Cancer Center at UH Avon Health Center Avon Ohio
United States Advocate Good Shepherd Hospital Barrington Illinois
United States UHHS-Chagrin Highlands Medical Center Beachwood Ohio
United States UPMC-Heritage Valley Health System Beaver Beaver Pennsylvania
United States Alta Bates Summit Medical Center-Herrick Campus Berkeley California
United States Tower Cancer Research Foundation Beverly Hills California
United States Rocky Mountain Cancer Centers-Boulder Boulder Colorado
United States Saint Joseph Mercy Brighton Brighton Michigan
United States Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton Michigan
United States Bryn Mawr Hospital Bryn Mawr Pennsylvania
United States Roswell Park Cancer Institute Buffalo New York
United States Saint Joseph Mercy Canton Canton Michigan
United States Trinity Health IHA Medical Group Hematology Oncology - Canton Canton Michigan
United States Saint Francis Medical Center Cape Girardeau Missouri
United States Carlisle Regional Cancer Center Carlisle Pennsylvania
United States Miami Valley Hospital South Centerville Ohio
United States Christiana Care Health System-Concord Health Center Chadds Ford Pennsylvania
United States Chambersburg Hospital Chambersburg Pennsylvania
United States Saint Joseph Mercy Chelsea Chelsea Michigan
United States Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea Michigan
United States Advocate Illinois Masonic Medical Center Chicago Illinois
United States Michigan Healthcare Professionals Clarkston Clarkston Michigan
United States Case Western Reserve University Cleveland Ohio
United States Memorial Hospital North Colorado Springs Colorado
United States UCHealth Memorial Hospital Central Colorado Springs Colorado
United States Siteman Cancer Center at West County Hospital Creve Coeur Missouri
United States AMG Crystal Lake - Oncology Crystal Lake Illinois
United States Geisinger Medical Center Danville Pennsylvania
United States Dayton Blood and Cancer Center Dayton Ohio
United States Miami Valley Hospital Dayton Ohio
United States Miami Valley Hospital North Dayton Ohio
United States Decatur Memorial Hospital Decatur Illinois
United States Iowa Methodist Medical Center Des Moines Iowa
United States Medical Oncology and Hematology Associates-Des Moines Des Moines Iowa
United States Fox Chase Cancer Center - East Norriton Hospital Outpatient Center East Norriton Pennsylvania
United States Marshfield Medical Center-EC Cancer Center Eau Claire Wisconsin
United States Crossroads Cancer Center Effingham Illinois
United States Advocate Sherman Hospital Elgin Illinois
United States UPMC Hillman Cancer Center Erie Erie Pennsylvania
United States Sanford Broadway Medical Center Fargo North Dakota
United States Sanford Roger Maris Cancer Center Fargo North Dakota
United States Michigan Healthcare Professionals Farmington Farmington Hills Michigan
United States UPMC Cancer Center at UPMC Horizon Farrell Pennsylvania
United States Piedmont Fayette Hospital Fayetteville Georgia
United States Cancer Care and Hematology-Fort Collins Fort Collins Colorado
United States Poudre Valley Hospital Fort Collins Colorado
United States Parkview Regional Medical Center Fort Wayne Indiana
United States Beebe South Coastal Health Campus Frankford Delaware
United States Atrium Medical Center-Middletown Regional Hospital Franklin Ohio
United States Fox Chase Cancer Center Buckingham Furlong Pennsylvania
United States Aurora Cancer Care-Grafton Grafton Wisconsin
United States UCHealth Greeley Hospital Greeley Colorado
United States Aurora BayCare Medical Center Green Bay Wisconsin
United States East Carolina University Greenville North Carolina
United States UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg Pennsylvania
United States Advocate South Suburban Hospital Hazel Crest Illinois
United States Penn State Milton S Hershey Medical Center Hershey Pennsylvania
United States UCHealth Highlands Ranch Hospital Highlands Ranch Colorado
United States Edwards Comprehensive Cancer Center Huntington West Virginia
United States IRMC Cancer Center Indiana Pennsylvania
United States Jupiter Medical Center Jupiter Florida
United States GenesisCare USA - Lakewood Ranch Lakewood Ranch Florida
United States Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire
United States Geisinger Medical Oncology-Lewisburg Lewisburg Pennsylvania
United States AMG Libertyville - Oncology Libertyville Illinois
United States Trinity Health Saint Mary Mercy Livonia Hospital Livonia Michigan
United States Cedars Sinai Medical Center Los Angeles California
United States Los Angeles General Medical Center Los Angeles California
United States USC / Norris Comprehensive Cancer Center Los Angeles California
United States Medical Center of the Rockies Loveland Colorado
United States Covenant Medical Center-Lakeside Lubbock Texas
United States Michigan Healthcare Professionals Macomb Macomb Michigan
United States Michigan Healthcare Professionals Madison Heights Madison Heights Michigan
United States Aurora Bay Area Medical Group-Marinette Marinette Wisconsin
United States Marshfield Medical Center-Marshfield Marshfield Wisconsin
United States UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg Pennsylvania
United States Riddle Memorial Hospital Media Pennsylvania
United States Froedtert Menomonee Falls Hospital Menomonee Falls Wisconsin
United States UH Seidman Cancer Center at Lake Health Mentor Campus Mentor Ohio
United States East Jefferson General Hospital Metairie Louisiana
United States LSU Healthcare Network / Metairie Multi-Specialty Clinic Metairie Louisiana
United States Aurora Saint Luke's Medical Center Milwaukee Wisconsin
United States Aurora Sinai Medical Center Milwaukee Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Marshfield Clinic-Minocqua Center Minocqua Wisconsin
United States Memorial Medical Center Modesto California
United States UPMC Hillman Cancer Center in Coraopolis Moon Pennsylvania
United States ProHealth D N Greenwald Center Mukwonago Wisconsin
United States Carolina Regional Cancer Center Myrtle Beach South Carolina
United States Cancer Center of Western Wisconsin New Richmond Wisconsin
United States Helen F Graham Cancer Center Newark Delaware
United States Medical Oncology Hematology Consultants PA Newark Delaware
United States Drexel Town Square Health Center Oak Creek Wisconsin
United States Advocate Christ Medical Center Oak Lawn Illinois
United States ProHealth Oconomowoc Memorial Hospital Oconomowoc Wisconsin
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California
United States Vince Lombardi Cancer Clinic - Oshkosh Oshkosh Wisconsin
United States Paoli Memorial Hospital Paoli Pennsylvania
United States The Valley Hospital-Luckow Pavilion Paramus New Jersey
United States Advocate Lutheran General Hospital Park Ridge Illinois
United States University Hospitals Parma Medical Center Parma Ohio
United States Methodist Medical Center of Illinois Peoria Illinois
United States OSF Saint Francis Medical Center Peoria Illinois
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Cancer Center at Saint Joseph's Phoenix Arizona
United States University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania
United States UPMC-Magee Womens Hospital Pittsburgh Pennsylvania
United States UPMC-Passavant Hospital Pittsburgh Pennsylvania
United States UPMC-Saint Margaret Pittsburgh Pennsylvania
United States UPMC-Shadyside Hospital Pittsburgh Pennsylvania
United States GenesisCare USA - Plantation Plantation Florida
United States Saint Joseph Mercy Oakland Pontiac Michigan
United States Oregon Health and Science University Portland Oregon
United States Geisinger Cancer Services-Pottsville Pottsville Pennsylvania
United States University Hospitals Portage Medical Center Ravenna Ohio
United States Beebe Health Campus Rehoboth Beach Delaware
United States Ascension Saint Mary's Hospital Rhinelander Wisconsin
United States Highland Hospital Rochester New York
United States University of Rochester Rochester New York
United States Delbert Day Cancer Institute at PCRMC Rolla Missouri
United States William Beaumont Hospital-Royal Oak Royal Oak Michigan
United States Norris Cotton Cancer Center-North Saint Johnsbury Vermont
United States Siteman Cancer Center at Christian Hospital Saint Louis Missouri
United States Siteman Cancer Center-South County Saint Louis Missouri
United States Washington University School of Medicine Saint Louis Missouri
United States Regions Hospital Saint Paul Minnesota
United States Siteman Cancer Center at Saint Peters Hospital Saint Peters Missouri
United States UPMC Cancer Center at UPMC Northwest Seneca Pennsylvania
United States Vince Lombardi Cancer Clinic-Sheboygan Sheboygan Wisconsin
United States Memorial Hospital East Shiloh Illinois
United States Sanford Cancer Center Oncology Clinic Sioux Falls South Dakota
United States Sanford USD Medical Center - Sioux Falls Sioux Falls South Dakota
United States Memorial Medical Center Springfield Illinois
United States Ascension Saint Michael's Hospital Stevens Point Wisconsin
United States Marshfield Medical Center-River Region at Stevens Point Stevens Point Wisconsin
United States Aurora Medical Center in Summit Summit Wisconsin
United States ProMedica Flower Hospital Sylvania Ohio
United States GenesisCare USA - Troy Troy Michigan
United States Upper Valley Medical Center Troy Ohio
United States William Beaumont Hospital - Troy Troy Michigan
United States UPMC Washington Hospital Radiation Oncology Washington Pennsylvania
United States UW Cancer Center at ProHealth Care Waukesha Wisconsin
United States Aspirus Regional Cancer Center Wausau Wisconsin
United States Aurora Cancer Care-Milwaukee West Wauwatosa Wisconsin
United States Wilmot Cancer Institute at Webster Webster New York
United States Aurora West Allis Medical Center West Allis Wisconsin
United States Froedtert West Bend Hospital/Kraemer Cancer Center West Bend Wisconsin
United States Marshfield Medical Center - Weston Weston Wisconsin
United States Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre Pennsylvania
United States Divine Providence Hospital Williamsport Pennsylvania
United States Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids Wisconsin
United States Lankenau Medical Center Wynnewood Pennsylvania
United States UPMC Memorial York Pennsylvania
United States WellSpan Health-York Cancer Center York Pennsylvania
United States Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti Michigan

Sponsors (2)

Lead Sponsor Collaborator
NRG Oncology National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiological progression-free survival (rPFS) The rPFS curves will be estimated by the Kaplan-Meier method and compared between the two treatment arms using a one-sided, logrank test stratified by the three randomization factors. Time from randomization to the occurrence of radiological progression detected by conventional imaging or death from any cause, assessed up to 5 years
Secondary Positron emission tomography (PET)-based radiological progression-free survival Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. Time from randomization to the occurrence of conventional or PET-based radiological progression or death from any cause, assessed up to 5 years
Secondary Metastasis-free Survival Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. From randomization to distant metastases or death from any cause, assessed up to 5 years
Secondary Overall Survival Will be estimated by the Kaplan-Meier method and compared between treatments arms by stratified logrank test. Cox regression models will also be fit, adjusted for the stratification factors and other prognostic baseline factors, to estimate hazard ratios, together with 95% confidence intervals. From randomization to death from any cause, assessed up to 5 years
Secondary Sexual Function Assessed by Expanded Prostate Cancer Index Composite Short Form (EPIC-26). Up to 5 years
Secondary Fatigue Assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue short form. Longitudinal profiles will be compared using mixed effects regression. Up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03796767 - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Phase 2
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT04175431 - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Phase 2
Completed NCT05197257 - 68Ga-PSMA-11 PET in Patients With Prostate Cancer Phase 3
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT02254746 - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer N/A
Active, not recruiting NCT05496959 - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Phase 2
Completed NCT02940262 - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Phase 3
Recruiting NCT04391556 - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma Phase 2
Enrolling by invitation NCT03503643 - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting NCT05832086 - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes Phase 2
Suspended NCT05064111 - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Recruiting NCT02600156 - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors N/A
Recruiting NCT05726292 - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Phase 2
Recruiting NCT04423211 - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging Phase 3
Terminated NCT03718338 - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated NCT02564549 - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca N/A